ProShare Advisors LLC Buys 10,900 Shares of Precigen, Inc. (NASDAQ:PGEN)

ProShare Advisors LLC grew its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 26.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,822 shares of the biotechnology company’s stock after purchasing an additional 10,900 shares during the period. ProShare Advisors LLC’s holdings in Precigen were worth $58,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Iridian Asset Management LLC CT boosted its stake in shares of Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock valued at $5,871,000 after purchasing an additional 1,465,962 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock valued at $3,696,000 after purchasing an additional 53,343 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Precigen by 4.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 56,012 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Precigen by 11.6% during the 4th quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company’s stock valued at $1,309,000 after purchasing an additional 121,700 shares in the last quarter. Finally, Fore Capital LLC lifted its position in Precigen by 27.7% during the 4th quarter. Fore Capital LLC now owns 391,811 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 85,000 shares during the period. Institutional investors own 33.51% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on PGEN shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Precigen in a research report on Thursday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Precigen in a report on Thursday, March 20th. Finally, Wall Street Zen cut shares of Precigen from a “hold” rating to a “sell” rating in a report on Saturday, May 24th.

Precigen Stock Performance

Shares of Precigen stock opened at $1.36 on Wednesday. The stock has a market capitalization of $401.44 million, a PE ratio of -2.47 and a beta of 1.82. Precigen, Inc. has a 52-week low of $0.65 and a 52-week high of $2.17. The company has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $1.34.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. As a group, equities research analysts forecast that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.